Maher A. Karam Hage, M.D.
Department of Behavioral Science, Division of Cancer Prevention and Population Sciences
About Dr. Maher A. Karam Hage
My interest in addiction is focused on the specific areas of tobacco, alcohol, and comorbid disorders. I started my career by designing, getting funded, and successfully completing my own study on bupropion for alcohol-dependent smokers. In the last 24 years, I have collaborated on more than 25 NIH-funded clinical trials as a co-investigator and study physician, and I participated in several pharmaceutical and investigator-initiated multi-site trials. I am an expert in evidence-based treatments for tobacco, alcohol, and opioid use disorders and an experienced medical educator in psychiatry and addiction.I have a keen interest in medical education and have designed and conducted several studies to enhance medical education on substance use disorders. Throughout the years, I have mentored several trainees in different capacities and from different disciplines. As the Medical Director of the Tobacco Treatment Program at UT MD Anderson Cancer Center, I continue to practice general and addiction psychiatry, and exercising my clinical skills, I derive my professional satisfaction from helping people recover from the grip of addiction, in particular smokers or tobacco users attempting to quit. In addition, I find clinical practice to be a unique and fertile ground to generate interesting and relevant clinical research questions: It is the ultimate venue for true translational research. I have collaborated with Drs. Robinson, Versace, Kypriotakis, and Cinciripini in my department for the last 18 years on several trials focused on improving the outcomes of treating smoking. We have published results on the effectiveness of our clinical program and several research studies, including previous neuroimaging studies to develop an innovative tailored approach to reduce vulnerability to nicotine self-administration. We are currently aiming to personalize the treatment by using genetic markers, as we conduct a major trial across Texas to recruit 2000 smokers; any smoker living in Texas can participate by going to www.nicotinestudy.org and answering a few screening questions. We also aim to personalize the treatment of repetitive Trans Magnetic Stimulation (rTMS) using the neuro-affective and neurocognitive biomarkers as the necessary preliminary step to successfully develop more effective, personalized noninvasive neuro-modulatory interventions for Substance Use Disorders.
Present Title & Affiliation
Primary Appointment
Medical Director of Tobacco Treatment Program, Department of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct, Professor, Department of Psychiatry, Baylor College of Medicine, Houston, TX
Professor (Joint Appointment), Department of Psychiatry, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor (Adjunct), Department of Psychiatry, Baylor College of Medicine, Houston, Tx
Professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor (Joint Appointment), Department of Psychiatry, The University of Texas MD Anderson Cancer Center, Houston, Tx
Education & Training
Degree-Granting Education
| 1993 | Facultad de Medicina at Universidad Francisco Marroquin (UFM), Ciudad de Guatemala, GT, Medicine, Medico y Cirujano (Doctor and Surgeon |
| 1989 | Facultad de Medicina at Universidad Francisco Marroquin (UFM), Guatemala City, GT, Bachalareus Scientiae (BS) |
Postgraduate Training
| 1999-2000 | Research Fellowship, Clinical Psychopharmacology, University of Michigan, Ann Arbor, Michigan |
| 1998-1999 | Clinical Fellowship, Addiction Psychiatry, University of Michigan, Ann Arbor, Michigan |
| 1994-1998 | Clinical Residency, General Psychiatry, University of Michigan, Ann Arbor, Michigan |
Licenses & Certifications
| 2022 | Georgia Composite Medical Board |
| 2022 | Washington State Department of Health |
| 2022 | Oklahoma State Board of Medical Licensure |
| 2022 | Tennessee Board of Medical Examiners |
| 2022 | Mississippi State Board of Medical Licensure |
| 2022 | Alabama Board of Medical Licensure |
| 2022 | Louisiana State Board Medical Licensure |
| 2022 | Arizona Board of Medical Licensure |
| 2022 | American Heart Association Certificate |
| 2022 | American Heart Association |
| 2022 | American Boards of Psychiatry & Neurology, Inc. (ABPN) |
| 2021 | Florida Department of Health Medical License |
| 2014 | American Board of Medical Quality |
| 2008 | Controlled Substance Registration Certificate United States Department of Justice Drug Enforcement Administration |
| 2006 | Texas State Board of Medical Licensure |
| 2006 | Medical License |
| 2003 | American Society of Addiction Medicine |
| 2002 | ABPN added qualification in Addiction Psychiatry |
| 1997 | State of Michigan Medical License |
| 1990 | Educational Commission for Foreign Medical Graduates |
Experience & Service
Faculty Academic Appointments
Associate Professor (Joint Appointment), Department of Psychiatry, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2015
Associate Professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2015
Assistant Professor, Department of Behavioral Science, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2006 - 2008
Assistant Professor (Joint Appointment), Department of Psychiatry, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2006 - 2008
Assistant Professor, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI, 2000 - 2006
Administrative Appointments/Responsibilities
Patient Safety and Quality Officer, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Associate Medical Director, Tobacco Treatment Program, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2017
Acting Director, Department of Addiction Psychiatry Fellowship, University of Michigan, Ann Arbor, MI, 2006 - 2006
Director of Medication Development and Testing, Department of Nicotine Research Program, University of Michigan, Ann Arbor, MI, 2004 - 2006
Associate Director, Department of Addiction Psychiatry Fellowship, University of Michigan, Ann Arbor, MI, 2003 - 2006
Director of Medical Education, Department of University of Michigan Addiction Treatment Services (UMATS), University of Michigan, Ann Arbor, MI, 2000 - 2006
Medical Director, Department of University of Michigan Addiction Treatment Services (UMATS), University of Michigan, Ann Arbor, MI, 2000 - 2006
Other Professional Positions
Physician Advocate Consultant and Speaker on Suboxone®, Reckitt-Benkiser Inc, N/A, 2005 - 2008
Intramural Institutional Committee Activities
Chair, Institutional Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2027
Member, Faculty Travel Affairs Committee (TAC), The University of Texas MD Anderson Cancer Center, 2025 - Present
Division of Cancer Prevention Representative, Physician Referral Service (PRS) Budget and Finance Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2027
Co-Chair, Professional Education Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Division of cancer prevention representative, PRS faculty retirement committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Chair, Professional Education Committee (PEC), The University of Texas MD Anderson Cancer Center, 2023 - 2025
Cancer Prevention Division Representative, Physician Referral Service (PRS) Executive Council, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Chair, Senior Faculty Committee - Academic Career Development, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
member, Nomination and Selection Committee for The Samuel J. Hassenbusch, MD, PhD, PRS Leadership & Institutional Service Award (The L.I.S.A), The University of Texas MD Anderson Cancer Center, 2022 - 2024
Member, Faculty Vitality & Engagement Council, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Member, Professional Education Committee (PEC), The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Employee Engagement Council, The University of Texas MD Anderson Cancer Center, 2020 - 2024
Member, Clinical Faculty Review Committee (CFRC), The University of Texas MD Anderson Cancer Center, 2020 - 2024
Member, Senior Faculty Committee - Academic Career Development, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, Practitioner Peer Assistance Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Division of Cancer Prevention Representative, Physician Referral Service (PRS) Budget and Finance Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Senate Faculty Salary Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2023
Vice Chair, Practitioner Peer Assistance Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, Travel Affairs Committee (TAC), The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Continuing Medical Education Committee (CME), The University of Texas MD Anderson Cancer Center, 2018 - 2021
Department Officer for Behavioral Science, Electronic Health Records, The University of Texas MD Anderson Cancer Center, 2018 - 2020
Member, Physician Referral Service (PRS) Faculty Compensation and Benefits Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Officer, Patient Safety Quality Officer (Behavioral Science), The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Psycho-Oncology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2024
Member, Mid-career Review for Karen Calabro, PhD, The University of Texas MD Anderson Cancer Center, 2016 - 2016
Member, Mid-tenure review for Eileen Shinn, PhD, The University of Texas MD Anderson Cancer Center, 2016 - 2016
Member, Practitioner Peer Assistance Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Officer, Department of Behavioral Science, EHR Implementation (EPIC), The University of Texas MD Anderson Cancer Center, 2014 - 2017
Reviewer, Faculty Awards Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2014
Officer, EHR Implementation (EPIC), The University of Texas MD Anderson Cancer Center, 2014 - 2017
Cancer Prevention Division Representative, Physician Referral Service (PRS) Executive Council, The University of Texas MD Anderson Cancer Center, 2013 - 2019
Reviewer, Faculty Awards for Clinical Research, Faculty Awards Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2013
Re-elected Senator for Behavioral Science, MD Anderson Cancer Center Faculty Senate, The University of Texas MD Anderson Cancer Center, 2013 - 2016
Member, Physician Referral Service (PRS) Budget Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2017
Member, Faculty Health and wellbeing Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2014
Senator for Behavioral Science, MD Anderson Cancer Center Faculty Senate, The University of Texas MD Anderson Cancer Center, 2010 - 2013
Member, House Officers' Association Web-Page, University of Michigan, The University of Texas MD Anderson Cancer Center, 2000 - 2001
Faculty Member, Residency Training Committee - University of Michigan Department of Psychiatry, The University of Texas MD Anderson Cancer Center, 2000 - 2006
Extramural Institutional Committee Activities
Member, ASAM's committee for position on e-cigarettes, American Society of Addiction Medicine, 2017
Member, General Psychiatry Residency Evaluation and Selection Committee, University of Michigan, 2000 - 2006
Resident Member, Residency Training Committee, University of Michigan, 1996 - 1997
Editorial Activities
Editorial Board Member, Journal of Psychiatry Research and Mental Health, 2017 - 2022
Editor/Service on Editorial Board(s), WebMD Central Plus (WCP), 2012 - 2014
Honors & Awards
| 2025 - Present | Faculty Excellence Award in Patient Safety and Quality of Care, The University of Texas MD Anderson Cancer Center |
| 2021 | Distinguished fellow, American Psychiatric Association |
| 2021 | Faculty Excellence Award, in prevention outreach, The University of Texas MD Anderson Cancer Center |
| 2017 | Faculty Excellence Award in Financial Stewardship, The University of Texas MD Anderson Cancer Center |
| 2016 | Julie and Ben Rogers Clinical Excellence Award 2016, The University of Texas MD Anderson Cancer Center |
| 2012 - 2013 | Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center |
| 2011 - Present | Fellow status of American Psychiatric Association, American Psychiatric Association |
| 2004 | Junior Investigator Colloquium Award, American Psychiatric Association meeting (New York) |
| 2002 - 2003 | Selected for the Medical Education Scholars Program, University of Michigan Medical School |
| 2000 | Junior Investigator Colloquium Award, American Psychiatric Association meeting (Chicago) |
| 1999 | Honorable mention & travel award addiction research, American Academy of Addiction Psychiatry (AAAP) annual meeting |
| 1999 | Recognition award for organizing & planning: 1st Addiction psychiatry day, Dept. Psychiatry, University of Michigan |
| 1998 | HO-IV education curriculum & teaching award, Dept. Psychiatry, U. of Michigan |
| 1998 - 1999 | Awarded 1-year research fellowship, American College of Neuropsychopharmacology |
| 1997 | Resident teaching residents Award, Dept. of Psychiatry, U. of Michigan |
| 1997 | Outstanding writing award: Best paper of the year, Dept. of Psychiatry, U of Michigan |
| 1994 | Romeo De Leon Award for medical school graduation thesis, Facultad de Medicina, UFM |
| 1991 | Medical school interchange program, Visiting Medical Student at Baylor College of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Need Name of Presentation. Invited. Tulane Addiction Medicine Fellowship Didactics. Houston, Texas, US.
- 2025. Pharmacotherapy For Tobacco Use Disorder: Advanced strategies. Invited. Tobacco Cessation Clinic Enhancement Program. Houston, Texas, US.
- 2023. Continuing to Smoke vs. Quitting and Impact on Psychiatric Comorbidities. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. What you need to know and how to help your patient quit smoking. The University of Texas MD Anderson Cancer Center - Grand Rounds. Houston, TX, US.
- 2020. The impact of treating comorbid psychiatric conditions on ability to quit smoking. The University of Texas MD Anderson Cancer Center - Grand Rounds. Houston, TX, US.
- 2018. Tobacco Treatment Program at MD Anderson, e-cigarettes, and opportunities for research collaborations. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Tobacco Use Disorder and E-cigarettes: Are they good for patients to quit smoking?. TSAM. Houston, TX, US.
- 2017. Improvement of Smoking Abstinence Rates with increased Varenicline Dosage: A Propensity Score Matched Analysis. Houston, TX, US.
- 2016. Treating MD Anderson Cancer Patients for Tobacco Use. Division of Internal Medicine, MD Anderson. Houston, TX, US.
- 2015. Remote Mentoring For Tobacco Cessation (ECHO project). Cancer Prevention Platform MD Anderson (Lung Moonshot Project). Houston, TX, US.
- 2015. Achieving Smoking Cessation. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Tobacco Use Disorder: Epidemiology, Biology and treatment. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Center for Recovering Families. Houston, TX, US.
- 2014. From clinical experience in tobacco cessation to clinical research trials: A two way street. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Houston Maintenance Clinic. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Montrose Center. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. El Dorado Texas Community Services. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Best Recovery. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Cheyenne Center. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Hauser Clinic and Associates. Houston, TX, US.
- 2014. Smoking cessation research studies at MD Anderson. Career and Recovery Resources. Houston, TX, US.
- 2013. Clinical MD Anderson Breakout Session: What will it take to enable telemedicine efforts at MD Anderson. Invited. MD Anderson Telemedicine and Telesurgery in Cancer Care Conference. Houston, Texas, US.
- 2013. What do we know about addiction? with focus on tobacco use and its treatments. National Arab American Medical Association. Houston, TX, US.
- 2013. Advances in Medicine. Prevention in Cancer: Focus on Tobacco Cessation. Invited. Houston, Texas, US.
- 2012. Tobacco Use, Identification and Treatment. Houston Psychiatric Society Meeting. Houston, TX, US.
- 2012. Assessing tobacco use and providing treatment (with Cinciripini PM, Rabius V). The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Assessing tobacco use and providing treatment (with Cinciripini PM, Rabius V). The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Assessing tobacco use and providing treatment (with Cinciripini PM, Rabius V). The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Assessing tobacco use and providing treatment (with Cinciripini PM, Rabius V). The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Tobacco: Reduce your risk. Tobacco and Cancer Risks. Houston, TX, US.
- 2009. Putting Research into Practice: Treating Tobacco Dependence in MD Anderson's Tobacco Treatment Program (with Blalock JA, Cinciripini PM). The University of Texas MD Anderson Cancer Center - Grand Rounds. Houston, TX, US.
- 2009. Advances and Future of Pharmacological Treatment of Nicotine Dependence (with Blalock JA, Cinciripini PM). The University of Texas MD Anderson Cancer Center -Institutional Grand Rounds. Houston, TX, US.
- 2009. Smoking Cessation. Cancer WISE Community Speaker's Bureau. Houston, TX, US.
- 2008. Texas Wellness and Smoking Policy Symposium. The Grip of Tobacco: The Science, Cessation and Future Strategies. Houston, TX, US.
- 2008. Tobacco and Nicotine Dependence: treatment updates. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. Nicotine Dependence, Smoking Cessation, & Translational Research. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2007. Opioid and Nicotine Addiction and Treatment Options. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2023. Smoking and your lungs. National Minority Quality Forum Connect: H-Town Health Fair. Virtual, US.
- 2023. Overcoming Addiction to Alcohol, Tobacco, and Illicit Substances. Khin Naing Foundation. Virtual, US.
- 2023. Initial tobacco treatment for cancer patients. Joe Arrington Cancer Research and Treatment Center. Lubbock, TX, US.
- 2019. Opioid Use Disorder and Implication on Texans health. University of Texas. Austin, TX, US.
- 2019. Impact of a Tobacco Treatment Program in Head and Neck Cancer Patients. Combined Otolaryngology Spring Meetings (COSM). Austin, TX, US.
- 2019. Opioid Use Disorder and its treatment. Association of Community Health Centers of Texas. Austin, TX, US.
- 2019. An Overview of Tobacco Prevention and Control Activities. Eliminate Tobacco Use Summit. Austin, TX, US.
- 2019. Opioid Use Disorder and its treatment. Texas Association of Community Health. Austin, TX, US.
- 2018. Tobacco Use Disorder: Impact on respiratory and cardiovascular health. Treatment Options. Texas Association of Cardiovascular and Pulmonary Rehabilitation. Austin, TX, US.
- 2016. Tobacco Cessation Treatment updates. Texas Research Society on Alcoholism. Dallas, TX, US.
- 2005. Newer Pharmacological Treatments For Alcohol Dependence. University of Michigan, MI, US.
- 2003. Medical Marijuana: Is There Such a Thing?. Michigan Society of Addiction Medicine. Detroit, MI, US.
- 2003. Addictions: what you need to know. University of Michigan Summer Science Academy. Ann Arbor, MI, US.
- 2003. Nicotine Effects On The Brain. University of Michigan Tobacco Consultation Service. Ann Arbor, MI, US.
- 2002. Is it good to quit smoking during early recovery?. University of Michigan. Ann Arbor, MI, US.
- 2001. Early Relapse Prevention to substances and pharmacotherapy. University of Michigan. Ann Arbor, MI, US.
- 2001. Nicotine and Psychiatry. University of Michigan. Ann Arbor, MI, US.
- 2000. DSM-IV and Substance Abuse/Dependence. Community Mental Health. Ann Arbor, MI, US.
- 1998. Alcohol and Sleep: Research Findings. University of Michigan, MI, US.
National Presentations
- 2025. Linking Training and Continuous Education: Developing a Comprehensive Approach to Tobacco Treatment Training. Poster. 2025 National Conference on Tobacco or Health. Chicago, IL, US.
- 2025. Improving Outcomes for Cancer Patients Through Tobacco Abstinence (Zoom). Invited. Jacksonville, FL, US.
- 2025. Examining Provider-Level Factors and Implementation Preconditions for Evidence-Based Policies and Procedures to Enact Systems Change in Opioid Treatment Programs to Address Disproportionately High Tobacco Use. Poster. Society for Research on Nicotine & Tobacco. New Orleans, LA, US.
- 2025. Developing a Shared Community of Practice for Treating Tobacco Use Disorder. Poster. Society For Research on Nicotine & Tobacco (SRNT). New Orleans, LA, US.
- 2024. Leveraging iECHO Model to Enhance Tobacco Treatment Services in Healthcare. Poster. Healthier Texas Summit 2024. Austin, TX, US.
- 2024. Addressing High Tobacco Use Rates at Opioid Treatment Centers through Comprehensive Tobacco-Free Workplace Programming: A Funded Clinical Quality Improvement Study Protocol. Poster. annual meeting of the American Academy of Health Behavior. Savannah, GA, US.
- 2024. Addressing High Tobacco Use Rates at Opioid Treatment Centers through Comprehensive Tobacco-Free Workplace Programming: A Funded Clinical Quality Improvement Study Protocol. Conference. American Academy of Health Behavior (AAHB). Savannah, GA, US.
- 2023. The Relationships of Childhood Trauma and Post-Traumatic Stress Disorder to Smoking Outcomes in Cancer Patients. Conference. Society for Research on Nicotine & Tobacco. San Antonio, TX, US.
- 2023. The Association Of Substance Use Disorder And Ability To Quit Smoking Among Cancer Patients. Conference. Society for Research on Nicotine and Tobacco Annual Meeting. San Antonio, TX, US.
- 2023. Cross-Validation Of Smoking Consumption Collections Using Timeline Follow-Back And Digital Diary. Conference. Society for Research on Nicotine and Tobacco Annual Meeting. San Antonio, TX, US.
- 2022. Increasing the accessibility of evidence-based treatment by transitioning the Tobacco Treatment specialist training to remote delivery. Conference. Society for Research on Nicotine and Tobacco Mtg. Baltimore, MD, US.
- 2022. Impact of Treating Insomnia Symptoms on Abstinence from Smoking - Poster. Conference. Society for Research on Nicotine and Tobacco. Baltimore, MD, US.
- 2022. Utilization and reliability of smartphone-enabled carbon monoxide devices in a remote smoking cessation trial. Conference. Society for Research on Nicotine and Tobacco Annual Meeting. Baltimore, MD, US.
- 2022. Association Between Quitting Smoking and Survival in Cancer Patients. Conference. Society for Research on Nicotine and Tobacco. Baltimore, MD, US.
- 2021. Treatment Options for Cancer and Non Cancer smokers. Invited. Ground Rounds at Lyndon B Johnson - Harris Health System. Houston, TX, US.
- 2021. What Providers Need to Know about Mental Health Treatment & Cancer. Invited. The National Council. Houston, TX, US.
- 2019. Connecting the Dots: Two Complementary Approaches to Enhance and Sustain Tobacco Treatment Practices within Health Systems. Conference. National Conference on Tobacco or Health. Minneapolis, MN, US.
- 2018. Real-Time Audio/Video Versus In-Person Treatment for Smoking. Conference. American Academy of Addiction Psychiatry. Bonita Springs, FL, US.
- 2017. The Impact of Treating Psychiatric Comorbidities On The Ability To Quit Smoking. Conference. San Diego, CA, US.
- 2016. Disseminating a Tele-mentoring Tobacco Cessation Case Consultation and Provider Education Model to Community Mental Health Centers in Texas. Conference. American Public Health Association Annual Meeting. Denver, CO, US.
- 2015. A multi-layered smoking cessation program for cancer patients: first year outcomes (Poster Presentation). Conference. 21st Annual Meeting Society for Research on Nicotine and Tobacco. Philadelphia, PA, US.
- 2014. Tobacco cessation and lung cancer screening: opportunities and challenges. Annual CHEST international conference. Austin, TX, US.
- 2014. Feasibility of using home-based mobile sensors for remote patient monitoring in cance care and prevention. Conference. American Society of Clinical Oncology Annual Conference. Chicago, IL, US.
- 2014. Bupropion XL has the same effectiveness and similar side effect profile as bupropion SR when used for smoking cessation among cancer patients. Conference. 2014 SRNT 20th Annual Meeting. Seattle, WA, US.
- 2013. Patients with serious psychiatric illness and tobacco addiction. Invited. American Academy of Addiction Psychiatry 24th Annual Meeting and Symposium. Scottsdale, AZ, US.
- 2013. Screening and therapeutic options for smoking cessation. Invited. 2013 Primary Care Summit - Dallas. Dallas, TX, US.
- 2013. Screening and therapeutic options for smoking cessations. Invited. 2013 Primary Care Summit - Houston. Houston, TX, US.
- 2013. Clinical MD Anderson Breakout Session: What will it take to enable telemedicine efforts at MD Anderson. Invited. MD Anderson Telemedicine and Telesurgery in Cancer Care Conference. Houston, TX, US.
- 2013. Treatment of Additions in emergency room. Residents and medical students. Invited. AUB Department of Psychiatry invited by the Chair, Dr. Ziad Nahas, Beirut, LB.
- 2013. Review of smoking cessation guideline treatment recommendations and recent advances in pharmacological intervention for nicotine dependence. Invited. GAP 2013 Conference. Houston, TX, US.
- 2013. Subjective ratings of cigarette-related, emotional, and neutral images in current smokers, smokers receiving smoking cessation treatment, and never-smokers. Poster. 2013 SRNT Annual Meeting. Boston, MA, US.
- 2013. Pioneering the delivery of tobacco cessation program to MD Anderson Regional Care Centers. Invited. Challenges for increasing access to cancer care in the digital era using Telemedicine. Houston, TX, US.
- 2012. Assessing tobacco use and providing tobacco cessation to cancer patients. Invited. American Association of Cancer Research Annual Meeting. Chicago, IL, US.
- 2012. Assessing tobacco use and providing tobacco cessation to cancer patients. Poster. American Association of Cancer Research Annual Meeting. Chicago, IL, US.
- 2012. Dissociation between brain responses to cigarette cues and natural rewards in smokers. Poster. 18th Annual Meeting of Society for Nicotine & Tobacco Research. Houston, TX, US.
- 2012. Smoking cessation as a function of physical and psychiatric comorbidities. Poster. 2012 SRNT 18th Annual Meeting. Houston, TX, US.
- 2011. Web-streamed Didactic Instruction on Substance Abuse Compares Favorably with Live Lecture Format. Poster. American Academy of Addiction Psychiatry 22nd Annual Meeting. Scottsdale, AZ, US.
- 2011. MD Anderson Cancer Center Tobacco Treatment Program: Effective smoking cessation assistance for cancer patients. Poster. CPRIT Innovations in Cancer Prevention Conference. Austin, TX, US.
- 2011. Effectiveness of smoking cessation assistance for cancer patients. Poster. 2011 SRNT 17th Annual Meeting. Toronto, Ontario, CA.
- 2010. Increasing Varenicline to 3 mgs/day Improves Abstinence Rates: A Preliminary Efficacy Report in Cancer Patients. Poster. Society For Research on Nicotine and Tobacco Annual Meeting. Baltimore, MD, US.
- 2008. Economic Evaluation of a Tobacco Cessation Program. Poster. European Congress 11th Annual Meeting. Athens, GR.
- 2007. Development of a clinical treatment pathways for a unique tobacco cessation program within a comprehensive cancer center. Poster. Oncology Nursing Society 2007 APN Conference. Chicago, IL, US.
- 2006. Medical Students Conduct Smoking Cessation Counseling. Poster. American Association for Cancer Education Annual Meeting. San Diego, CA, US.
- 2006. Effects of smoking cues on craving for alcohol and cigarettes in drinkers who smoke. Poster. Society for Research on Nicotine and Tobacco. Austin, TX, US.
- 2006. Sex specific differences between smokers with and without DSM-IV alcohol abuse. Poster. Society for Research on Nicotine and Tobacco Annual Meeting. Orlando, FL, US.
- 2006. Characteristics of early and late onset smokers. Poster. Society for Research on Nicotine and Tobacco Annual Meeting. Orlando, FL, US.
- 2006. Acquired Knowledge of Addiction Among Psychiatry Residents by Repeat Testing. Poster. American Academy of Addiction Psychiatry (AAAP) 17th Annual Meeting. St. Petersburg, FL, US.
- 2006. Impact of DSM-IV lifetime alcohol use disorders, depression and the two combined on smoking-related variables. Poster. Society for Research on Nicotine and Tobacco Annual Meeting. Orlando, FL, US.
- 2006. Psychiatric patients at intake: Tobacco use profile and interest in quitting smoking. Poster. Society for Research on Nicotine and Tobacco Annual Meeting. Orlando, FL, US.
- 2004. Unaided smoking cessation at six-month follow-up in smokers in treatment for alcohol dependence. Poster. Blending Research and Clinical Practice Conference. Detroit, MI, US.
- 2004. Cigarette & alcohol cue reactivity in alcoholic smokers. Invited. American Psychiatric Association Annual Meeting. New York, NY, US.
- 2004. Differences between smokers with and without a history of excessive alcohol use. Poster. Society of Research on Nicotine and Tobacco Annual Meeting. Scottsdale, AZ, US.
- 2004. Unaided smoking cessation at six-month follow-up in smokers in treatment for alcohol dependence. Poster. Society of Research on Nicotine and Tobacco Annual Meeting. Scottsdale, AZ, US.
- 2003. Motivational Interviewing Workshop. Invited. American Academy of Addiction Psychiatry. Scottsdale, AZ, US.
- 2003. Evaluating Acquired Knowledge of Addiction Among Psychiatry Residents by Repeat Testing. Poster. American Academy of Addiction Psychiatry Annual Meeting. New Orleans, LA, US.
- 2003. Nicotine Dependency. Invited. Michigan Society of Addiction Medicine, MI, US.
- 2003. A Randomized, Double Blind Pilot Trial of Gabapentin vs. Placebo to Treat Alcohol Dependence. Poster. 58th Annual Meeting Biologic Psychiatry. San Diego, CA, US.
- 2002. Mini-outcome study of treatment at CATC. Poster. Summer Biomedical Research Program, US.
- 2002. Bupropion for Smoking Cessation/Reduction Among Alcoholics During Early Recovery: Open trial. Poster. Society of Research on Nicotine and Tobacco (SRNT) Annual Meeting. Savannah, GA, US.
- 2001. Mu Opioid Receptor Binding In Alcohol Dependent Volunteers In Early Recovery: Clinical Correlates. Poster. American College of Neuropsychopharmacology Annual Meeting. Big Island, HI, US.
- 2001. Bupropion Tx for Smoking Cessation Alcoholics During Early Recovery. Poster. Society of Research on Nicotine and Tobacco (SRNT) Annual Meeting. Seattle, WA, US.
- 2000. Smoking Cessation Among Alcoholics in Early Recovery, a Review. Conference. AAAP Annual Meeting. Phoenix, AZ, US.
- 2000. Gabapentin Superior to Trazodone in Treating Insomnia among Alcoholics in Early Recovery. Poster. ACNP Annual Meeting, Puerto Rico, US.
- 2000. Trazodone Versus Gabapentin For Treatment of Insomnia of Alcoholics in Early Recovery. Poster. Research Society on Alcoholism (RSA) Annual Meeting. Denver, CO, US.
- 2000. Polysomnography Pre- and Post-Gabapentin For Insomnia in Alcoholic Outpatients: Preliminary Findings. Poster. American Academy of Sleep Medicine Annual Meeting. Las Vegas, NV, US.
- 2000. Bupropion For Smoking Cessation Among Alcoholics During Early Recovery. Conference. American Psychiatric Association (APA) Annual Meeting. Chicago, IL, US.
- 1999. Successful Treatment of Insomnia with Gabapentin in Alcoholics. Poster. Research Society on Alcoholism (RSA) Annual Meeting. Santa Barbara, CA, US.
- 1998. Gabapentin Treatment of Sleep Disturbance In Substance Dependent Patients. Poster. American College of Neuropsychopharmacology Annual Meeting, Puerto Rico, US.
- 1998. Patients' Use of The Internet In a Psychiatric Clinic. Poster. Institute on Psychiatric Services Annual Meeting. Los Angeles, CA, US.
- 1998. Dual Diagnosis Treatments and Mechanisms. Invited. National Alliance for the Mentally Ill (NAMI). Ann Arbor, MI, US.
- 1998. Persistent Sleep Disturbance In Problem Drinkers, Psychiatric Severity and Depression. Poster. Research Society on Alcoholism Annual Meeting. Hilton Head, SC, US.
- 1996. Oxytocin Regulation of Glutamate Receptors at AMPA. Conference. American Psychiatric Association Annual Meeting. New York, NY, US.
- 1996. Low Dose Neuroleptics is Beneficial for Negative Symptoms of Schizophrenia. Conference. American Psychiatric Association Annual Meeting. New York, NY, US.
International Presentations
- 2024. The Effects of Smoking Cessation on Overall Survival Among Patients with and without Cancer. Conference. Society for Research on Nicotine & Tobacco Annual Meeting. Edinburgh, GB.
- 2022. Smoking cessation in Breast Cancer. Invited. Dubai International Oncology & Supportive Care Congress. Dubai, AE.
- 2021. Actual treatment and challenges in smoking cessation treatment, "Novedades y retos en el tratamiento para dejar de fumar". Invited. La Sociedad Mexicana De Neumologia y Cirugia de Torax. Mexico City, MX.
- 2018. Tobacco Use Disorder: Neurobiology, treatment and Future directions by FDA. Invited. Lebanese American University-Medical Center. Beirut, LB.
- 2017. Emerging data on treating heavily addicted smokers: higher doses of Varenicline and combining Varenicline with Bupropion Maher Karam-Hage. Invited. Invited by Princess Ghida Bin Talal. Amman, JO.
- 2017. Monitoring Tobacco Dependence Treatment Services: learning from the experience of MD Anderson. Invited. Invited by Princess Ghida Bin Talal. Amman, JO.
- 2017. Comorbid common psychiatric condition and the impact on the ability to quit smoking. Invited. Invited by Princess Ghida Bin Talal. Amman, JO.
- 2017. Increasing Varenicline to 3mg Per Day Improves Smoking Abstinence: A propensity Score Analysis. Conference. SRNT Annual Meeting. Florence, IT.
- 2016. Research and New Treatments For Tobacco Use Disorder. Invited. 17th World Conference on Lung Cancer. Vienna, AT.
- 2016. A Comprehensive Tobacco Treatment Program. Invited. Aman, JO.
- 2016. Advances in Tobacco Cessation. Invited. American University of Beirut. Beirut, LB.
- 2014. The smoking gun: how we handle tobacco. Invited. The 14th International American Lebanese Medical Association Congress. Beirut, US.
- 2013. Panel discussion as part of planning symposium for naufar treatment center. Invited. Naufar Project, QA.
- 2013. Basics of tobacco treatment. Invited, TR.
- 2013. Use of electronic health records increases referrals to the Tobacco Treatment Program at MD Anderson Cancer Center. Poster. 2013 SRNT 19th Annual International Meeting. Boston, US.
- 2012. Tobacco Dependence: Advanced treatment strategies to psychiatrists, psychologists and healthcare providers. Invited. Implications of the New Tobacco Law. Beirut, LB.
- 2012. Diagnosing and Treating Alcohol and Tobacco Among Head and Neck Patients. Invited. 8th International Conference Society of Head and Neck Cancer. Toronto, CA.
- 2011. Smoking Addiction: Current and Future treatment options. Invited. American Lebanese Medical Association. Beirut, LB.
- 2011. A Comprehensive Tobacco-Cessation Treatment for Cancer Patients: 12-Month follow-up Abstinence Rates. Poster. 2011 SRNT 17th Annual Meeting. Toronto, CA.
- 2009. Nicotine Withdrawal in Chronically Depressed Smokers Undergoing Intensive Smoking Cessation Treatment. Poster. 14th Annual World Conference on Tobacco or Health. Mumbai, IN.
- 2006. Treatment of Alcohol Dependence. Invited. Sheikh Khalifa Medical City. Abu Dhabi, AE.
- 2006. Smoking Cessation: The Know How. Invited. Sheikh Khalifa Medical City. Abu Dhabi, AE.
- 2005. Differential Impact of DSM-IV Alcohol Abuse and Dependence On Smoking. Poster. Society for Research on Nicotine and Tobacco Annual Meeting. Prague, CZ.
- 2005. Differences in response to initial experimentation with smoking in never smokers based on fam history of smoking & problem drinking. Poster. Society for Research on Nicotine and Tobacco Research Annual Meeting. Prague, CZ.
- 2001. Bupropion Treatment for Smoking Alcoholics and expired CO. Poster. RSA Annual Meeting. Montreal, CA.
- 1999. Modifying Residents’ Professional Attitudes About Substance Abuse Tx & Training. Poster. American Academy of Addiction Psychiatry (AAAP) Annual Meeting. Nassau, BS.
- 1999. Mu Opioid Receptor Binding In Alcohol Dependent Volunteers In Early Recovery. Poster. Am. Col. of Neuropsychopharmacology (ACNP) Annual Meeting. Acapulco, MX.
Formal Peers
- 2024. Tobacco Use, Prevention Strategies and Lung Cancer Screening. Invited. Houston, TX, US.
- 2024. Update on treatment options for tobacco disorder. Visiting. Houston, TX, US.
- 2024. Initial Interventions For Treating Tobacco Use Disorder. Invited. Dallas, TX, US.
- 2024. Tobacco treatment comorbidities and obstacles. Invited. Washington DC, US.
- 2022. Electronic cigarettes, vaping and new synthetic nicotine: Are they good or harmful for public health. Invited. Houston, TX, US.
- 2022. Telehealth & Related Technologies to Help Patients Quit Smoking, Vaping and other Tobacco. Invited, US.
- 2020. Screening For and Treating Tobacco Use Disorder to Prevent Lung Cancer. Invited. Tyler, TX, US.
- 2020. Tobacco treatment at MD Anderson. Invited. Houston, TX, US.
- 2020. Medication Treatment for tobacco Use disorder. Invited. Houston, TX, US.
- 2019. Opioid Use Disorder and its treatment. Invited. Pearland, TX, US.
- 2019. Tobacco Treatment and Lung Cancer Screening. Invited. Houston, TX, US.
- 2019. Smoking Cessation and Lung Cancer Screening Shared Decision Making. Invited. Houston, TX, US.
- 2019. Tobacco Use Disorder and Its Treatment. Invited. Houston, TX, US.
- 2017. Achieving Freedom from Tobacco Use. Visiting. Nags Head, NC, US.
- 2017. How to Screen and Help Your Patients Achieve Freedom from Tobacco: Evidence-Based Strategies and Best Practices from MD Anderson Cancer Center. Visiting. Nags Head, NC, US.
- 2017. How To Build A Tobacco Treatment Program. Invited. Charlotte, NC, US.
- 2017. Tobacco Use Disorder and treatment for Mental Health and Substance Use Disorders. Invited. Jacksonville, FL, US.
- 2017. Smoking, Tobacco and Nicotine products: Risk for cancer. Invited. Galveston, TX, US.
- 2013. Tobacco treatment: current and future pharmacological options. Visiting. Houston, TX, US.
- 2012. Smoking Cessation: the basics for Medical Trainees. Visiting. Beirut, Lebanon, LB.
- 2011. Tobacco: Reduce your cancer risks. Invited. Houston, TX, US.
- 2010. Tobacco cessation as cancer prevention. Invited, US.
- 2009. Clinical Access and Efficiency. Invited. Austin, TX, US.
- 2006. Smoking and depression comorbidity and treatment options (with Duffy S). Invited. Ann Arbor, MI, US.
- 2006. What is and how to use Suboxone (buprenorphine). Invited. Ann Arbor, MI, US.
- 2006. How to Recognize Children and Adolescents Substance Use. Invited. Dearborn, MI, US.
- 2006. Using Suboxone (buprenorphine) for hospital detoxification. Invited, MI, US.
- 2006. New Trends in Substance Abuse Treatments. Invited. Ann Arbor, MI, US.
- 2005. How to Recognize Children and Adolescents Substance Use. Invited, MI, US.
- 2005. Buprenorphine the basics. Invited, MI, US.
- 2005. Dual Diagnosis and the Minkoff Model. Invited. Albion, MI, US.
- 2005. How to Recognize Children and Adolescents Substance Use. Invited, MI, US.
- 2005. Buprenorphine the basics. Invited, MI, US.
- 2005. What is addiction and what to look for. Invited. Ann Arbor, MI, US.
- 2005. How to Recognize Children and Adolescents Substance Use. Invited, MI, US.
- 2004. Pain and the Substance Abusing Patient. Invited. Ann Arbor, MI, US.
- 2004. Children and Adolescents substance use. Invited. Ann Arbor, MI, US.
- 2004. How to Recognize Children and Adolescents Substance Use. Invited, MI, US.
- 2003. Guidelines for Smoking Cessation. Invited. Ann Arbor, MI, US.
- 2003. Children and Adolescents substance use. Invited. Ann Arbor, MI, US.
- 2003. Nuts and Bolts of Quitting smoking. Invited. Ann Arbor, MI, US.
- 2003. Substance Abuse in the Emergency Room. Invited. Ann Arbor, MI, US.
- 2002. DSM-IV and Epidemiology of Substance Abuse/Dependence. Invited. Ann Arbor, MI, US.
- 2002. Determinants of Addictive Behaviors. Invited. Detroit, MI, US.
- 2001. Pharmacotherapy and Relapse Prevention. Invited. Ann Arbor, MI, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Reducing Cancer Recurrence Risk Through Combination Therapy in Survivors Motivated to Quit Smoking: a Randomized Clinical Trial |
| Funding Source: | National Institutes of Health |
| Role: | Co-PI |
| ID: | GRANT 14504932 |
| Date: | 2026 - 2031 |
| Title: | BILI-DC: BRAIN IMAGING AND LIFESTYLE INTERVENTIONS FOR IMMUNOTHERAPY-RELATED INFLAMMATORY DEPRESSION IN CANCER PATIENTS |
| Funding Source: | National Institutes of Health |
| Role: | Co-PI |
| ID: | GRANT 14504288 |
| Date: | 2026 - 2031 |
| Title: | Imprint: Investigating Mechanisms and Personalized Interventions for Immunotherapy-Induced Depression |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | GRANT14421931 |
| Date: | 2026 - 2028 |
| Title: | Feasibility of a Multi-Modal Digital Smoking Reduction Intervention to Promote Cessation for Cancer Patients |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | Co-I |
| ID: | FP00026602 |
| Date: | 2026 - 2029 |
| Title: | Personalized Neuromodulation for Obesity: A Bayesian Approach |
| Funding Source: | National Institutes of Health |
| Role: | Co-I |
| ID: | 1R01DK146869-01 |
| Date: | 2025 - 2028 |
| Title: | Personalized Brain Stimulation to Combat Obesity and Reduce Cancer Risk |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | Co-I |
| ID: | RP260065 |
| Date: | 2025 - 2028 |
| Title: | OUTPACE Tobacco: Scaling Up Tobacco-Free Workplace Initiatives in Texas Opioid Treatment Programs |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | PP260002 |
| Date: | 2025 - 2030 |
| Title: | Advanced Precision Medicine in Cancer-Related Depression through Computational Approaches |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 1UG3MH141001-01 |
| Date: | 2024 - 2026 |
| Title: | Bayesian neurobehavioral phenotyping: from mechanism identification to personalized neuromodulation treatments |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R61DA058276-01A1 |
| Date: | 2024 - 2027 |
| Title: | UT Foundation on behalf of MD Anderson, Eliminate Tobacco Use Initiative + |
| Funding Source: | Elevance Health Foundation |
| Role: | Co-I |
| Date: | 2024 - 2028 |
| Title: | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimal Smoking Cessation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA278938-01A1 |
| Date: | 2023 - 2028 |
| Title: | Cancer Prevention Education: Student Research Experiences |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | 5R25CA056452-29 |
| Date: | 2023 - 2028 |
| Title: | Supporting Tobacco-Related Ongoing Education and Research (STRONGER) Scholar Program |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | 1R25DA059907-01 |
| Date: | 2023 - 2028 |
| Title: | Penn State TCORS Project 3: Randomized Placebo-controlled Trial of Nicotine Pouches in Smokers |
| Funding Source: | NIH/NIDA |
| Role: | Co-I |
| ID: | U54DA058271 |
| Date: | 2020 - 2026 |
| Title: | The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA238478 |
Selected Publications
Peer-Reviewed Articles
- Robinson JD, Anthenelli RM, Cinciripini PM, Karam Hage MA, Cui Y, Kypriotakis G, Tiouririne A N. High- and Low-Dose Topiramate for the Treatment of Persons with Alcohol Use Disorder Who Smoke Cigarettes: A Randomized Control Trial. Alcohol, Clinical and Experimental Research. e-Pub 2025.
- Robinson JD, Cui Y, Karam-Hage M, Blalock JA, Shete S, Kypriotakis G, Yang P, Cinciripini PM. Standardized research electronic cigarette acceptability among adult men and women who smoke combustible cigarettes. Psychol Addict Behav , 2025. PMID: 41051837.
- Beneventi D, Kypriotakis G, Kotsen C, Karam-Hage M, Robinson JD, Minnix JA, Cinciripini PM. Real-world comparison of phone versus video consultation in a tobacco treatment program during the COVID-19 pandemic. Patient Educ Couns 141, 2025. PMID: 40945190.
- Minnix JA, Kypriotakis G, Blalock JA, Green CE, Karam-Hage M, Robinson JD, Cinciripini PM. Characterization of Cognitive-Behavioral Counseling Duration Thresholds for Effective Tobacco Treatment. Nicotine Tob Res, 2025. e-Pub 2025. PMID: 40847822.
- Robinson JD, Cui Y, Kypriotakis G, Engelmann JM, Karam-Hage M, Minnix JA, Green CE, Shete S, Hatsukami DK, Donny EC, Murphy SE, Hecht SS, Eissenberg T, Wetter DW, Cinciripini PM. Evaluating the human abuse potential of concurrent use of electronic cigarettes and low nicotine cigarettes among adults who smoke. Exp Clin Psychopharmacol 33(2):133-144, 2025. e-Pub 2025. PMID: 39541521.
- Cinciripini PM, Minnix JA, Kypriotakis G, Erasmus J, Beneventi D, Karam-Hage M, Carpenter K, Volk RJ, Carter B, B Godoy MC, Strange C, Shih YT, Cui Y, Green CE, Robinson JD. Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Randomized Clinical Trial. JAMA Intern Med 185(3):284-291, 2025. e-Pub 2025. PMID: 39804633.
- Kypriotakis G, Cinciripini PM, Green C, Lawrence D, Anthenelli RM, Minnix JA, Beneventi D, Morris C, Karam-Hage M, Blalock JA. Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry 182(2):174-186, 2025. e-Pub 2025. PMID: 39659160.
- Cinciripini PM, Kypriotakis G, Blalock JA, Karam-Hage M, Beneventi DM, Robinson JD, Minnix JA, Warren GW. Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis. JAMA Oncol 10(12):1689-1696, 2024. e-Pub 2024. PMID: 39480450.
- Willett JG, Karam-Hage M. Winning the Tobacco Endgame. Health Affairs Forefront, 2024. e-Pub 2024.
- Rodríguez-Cano R, Kypriotakis G, Robinson JD, Karam-Hage M, Blalock JA, Minnix JA, Beneventi D, Cinciripini PM. Comparing the Fagerström Test and Heaviness of Smoking Index in Predicting Smoking Abstinence in Cancer Patients. Nicotine Tob Res 26(11):1576-1581, 2024. e-Pub 2024. PMID: 38785358.
- Cinciripini PM, Green CE, Shete S, Minnix JA, Robinson JD, Cui Y, Kim S, Kypriotakis G, Beneventi D, Blalock JA, Versace F, Karam-Hage M. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement. JAMA 331(20):1722-1731, 2024. e-Pub 2024. PMID: 38696203.
- Kypriotakis G, Kim S, Karam-Hage M, Robinson JD, Minnix JA, Blalock JA, Cui Y, Beneventi D, Kim B, Pan I, Shih YT, Cinciripini PM. Examining the Association between Abstinence from Smoking and Healthcare Costs Among Patients with Cancer. Cancer Prev Res (Phila) 17(5):217-225, 2024. e-Pub 2024. PMID: 37940143.
- Cui Y, Robinson JD, Kypriotakis G, Minnix JA, Green CE, Kim S, Karam-Hage M, Cinciripini PM. Comparable cigarette consumption data collected using timeline follow-back and digital diary among treatment-seeking smokers. Psychol Addict Behav 38(3):315-322, 2024. e-Pub 2024. PMID: 37747518.
- Robinson JD, Kypriotakis G, Karam-Hage M, Cui Y, Beneventi D, Blalock JA, Minnix JA, Cinciripini PM. Brief report: Characterization of electronic cigarette use among patients of a comprehensive cancer center. Am J Addict 33(3):339-342, 2024. e-Pub 2024. PMID: 37807121.
- Britton M, Le C, Martinez Leal I, Rogova A, Chen TA, Karam-Hage M, Cinciripini PM, Sanchez H, Reitzel LR. Addressing High Tobacco Use Rates at Opioid Treatment Centers Through Comprehensive Tobacco-Free Workplace Programming: A Funded Clinical Quality Improvement Study Protocol. American Academy of Health Behavior 7(2), 2024. e-Pub 2024.
- Bayley EM, Zhou N, Mitchell KG, Antonoff MB, Mehran RJ, Rice DC, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Cinciripini PM, Karam-Hage M, Roth JA, Hofstetter WL. Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. Ann Thorac Surg 114(1):286-292, 2022. e-Pub 2022. PMID: 34358522.
- Robinson JD, Karam-Hage M, Kypriotakis G, Beneventi D, Blalock JA, Cui Y, Gonzalez R, Tayar J, Chaftari P, Cinciripini PM. Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. Am J Addict 31(3):236-241, 2022. e-Pub 2022. PMID: 35347796.
- Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, Blalock JA, Beneventi D, Morris C, Karam-Hage M. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety 39(5):1-12, 2022. e-Pub 2022. PMID: 35535436.
- Raghavendra AS, Kypriotakis G, Karam-Hage M, Kim S, Jizzini M, Seoudy KS, Robinson JD, Barcenas CH, Cinciripini PM, Tripathy D, Ibrahim NK. The Impact of Treatment for Smoking on Breast Cancer Patients' Survival. Cancers (Basel) 14(6):1464, 2022. e-Pub 2022. PMID: 35326615.
- Robinson JD, Cui Y, Karam-Hage M, Kypriotakis G, Versace F, Tiouririne NA, Anthenelli RM, Cinciripini PM. Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder. Alcohol Clin Exp Res 46(3):384-395, 2022. e-Pub 2022. PMID: 35037278.
- Peterson SK, Basen-Engquist K, Demark-Wahnefried W, Prokhorov AV, Shinn EH, Martch SL, Beadle BM, Garden AS, Farcas E, Brandon Gunn G, Fuller CD, Morrison WH, Rosenthal DI, Phan J, Eng C, Cinciripini PM, Karam-Hage MA, Camero Garcia M, Patrick K. Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention. AMIA Annu Symp Proc 2021:979-988, 2022. e-Pub 2022. PMID: 35308916.
- Cui Y, Abrego PL, Yoon JH, Karam-Hage M, Cinciripini PM, Tiouririne NA, Anthenelli RM, Robinson JD. Behavioral Economic Assessment of Alcohol and Cigarette Demand in Smokers With Alcohol Use Disorder. Front Psychiatry 12:674607, 2021. e-Pub 2021. PMID: 34248711.
- Sheffer CE, Al-Zalabani A, Aubrey A, Bader R, Beltrez C, Bennett S, Carl E, Cranos C, Darville A, Greyber J, Karam-Hage M, Hawari F, Hutcheson T, Hynes V, Kotsen C, Leone F, McConaha J, McCary H, Meade C, Messick C, Morgan SK, Morris CW, Payne T, Retzlaff J, Santis W, Short E, Shumaker T, Steinberg M, Wendling A. The Emerging Global Tobacco Treatment Workforce: Characteristics of Tobacco Treatment Specialists Trained in Council-Accredited Training Programs from 2017 to 2019. Int J Environ Res Public Health 18(5):2416, 2021. e-Pub 2021. PMID: 33801227.
Invited Articles
- Karam-Hage M, Minnix J, Cinciripini P. Alcohol and smoking cessation for cancer survivors. UpToDate, 2023. e-Pub 2023.
Review Articles
- Hurst A, Karam Hage MA, Cofer J, Javaid M, Beneventi D, Blalock J, Winter T, Cinciripini PM, Hawk E. A Tobacco Treatment Training Program Expands the Number of Healthcare Providers Trained to Use Evidence-Based Practices and Methods. Advances in Cancer Education and Quality Improvement 1(1), 2025. e-Pub 2025.
Abstracts
- Moosa AB, Britton M, Leal IM, Wani H, Chen TA, Beneventi DM, Minnix JA, Karam-Hage MA, Cinciripini PM, Zere M, Zere M, Thornton D, Reitzel LR. Preventing tobacco-related cancer disparities among opioid use treatment program stakeholders: A case study of a tailored tobacco-free workplace program implementation with reach to rural/medically underserved areas of Texas. 18th AACR Conference on the Science of Cancer Health Disparities 34(9_Supplement):B014, 2025. e-Pub 2025.
- Nguyen C, Karam-Hage M, Kypriotakis G, Robinson J, Minnix J, Beneventi D, Cinciripini P. Impact of Panic Disorder on Smoking Cessation Among Cancer Patients in a Tobacco Treatment Program. Society for Research on Nicotine & Tobacco, 2025. e-Pub 2025.
- Cofer J, Hurst A, Karam-Hage M, Blalock JA, Beneventi DM, Evans M, Wippold RC, Antwi A, Cinciripini PM. Linking an intensive training program to a subsequent weekly tele-mentoring session to increase and sustain healthcare providers’ knowledge in a behavioral health setting; Creating the Healthiest Nation: Health Equity Now, 2025. e-Pub 2025.
- Britton M, Le C, Leal M I, Rogova A, Chen TA, Karam-Hage M, Cinciripini PM, Sanchez H, Reitzel LR. Addressing High Tobacco Use Rates at Opioid Treatment Centers Through Comprehensive Tobacco-Free Workplace Programming: A Funded Clinical Quality Improvement Study Protocol. American Academy Health Behavior Research, 2024. e-Pub 2024.
Book Chapters
- Roberto Gonzalez MD, Maher Karam-Hage MD. Behavioral Approaches to Cancer Prevention. In: Holland-Frei Cancer Medicine. 10th edition. Wiley Blackwell, 2022.
Patient Reviews
CV information above last modified November 14, 2025